Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01502631 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT01502631 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 65 participants.
The verdict
NCT01502631, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this research study is to gather scientific information about the effectiveness of the study drug, SUN13837 Injection, when compared with the placebo (inactive substance) in participants with acute spinal cord injury.
Interventions
- DRUG Placebo
- DRUG SUN13837 injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2012-08-08 |
| Est. Completion | 2014-09-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01502631
The ClinicalTrials.gov registry entry for NCT01502631 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01502631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01502631 about?
NCT01502631 is a clinical study titled "Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)". The purpose of this research study is to gather scientific information about the effectiveness of the study drug, SUN13837 Injection, when compared with the placebo (inactive substance) in participants with acute spinal cord injury.
What is the current status of trial NCT01502631?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2012-08-08. Estimated completion is 2014-09-21.
What interventions are being tested in trial NCT01502631?
The interventions under investigation include: Placebo (DRUG), SUN13837 injection (DRUG).
Who is sponsoring clinical trial NCT01502631?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.